MS4A4E Oligonucleotide Inhibition for Liver Fibrosis and NASH
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a growing prevalence of liver disorders such as fatty liver diseases, non-alcoholic steatohepatitis (NASH), liver fibrosis, and cirrhosis, for which effective therapeutic options are lacking.
Innovation Solution
Compositions comprising MS4A4E inhibitors, particularly oligonucleotides like siRNA or ASO, are administered to target and reduce MS4A4E expression, thereby decreasing liver disease markers and metabolic disorder measurements.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutics are used for liver disorders, then treatment options are limited, but liver disease progression continues unchecked
Solution Approach 1:
The patent segments the therapeutic approach by targeting specific molecular pathways (MS4A4E gene and protein) rather than using broad-spectrum conventional therapies. This segmentation enables precise intervention in liver disease pathogenesis, addressing the limitation of non-specific conventional treatments while maintaining reliable therapeutic efficacy through mechanism-based action.
Solution Approach 2:
The patent applies parameter changes by modulating MS4A4E expression levels and activity through targeted inhibition. This changes the biochemical parameters of liver disease progression, transforming the therapeutic landscape from limited conventional options to a new parameter space of gene and protein level modulation, thereby expanding treatment versatility while ensuring efficacy.
2Reliability
If MS4A4E expression is reduced, then liver disease markers decrease, but requires precise molecular targeting
Solution Approach 1:
The patent uses MS4A4E as an intermediary target between the oligonucleotide therapy and the downstream liver disease pathology. By inhibiting MS4A4E expression and function, the therapy creates a controlled intermediary step that reliably reduces liver disease markers while managing the complexity of molecular targeting through a single focused mechanism rather than direct intervention in complex disease pathways.
3Reliability
If oligonucleotide therapy is administered, then metabolic parameters improve, but requires sustained effective dosing
Solution Approach 1:
The patent ensures continuity of useful action through sustained oligonucleotide dosing regimens that maintain MS4A4E inhibition over time. This continuous therapeutic action on the molecular target translates to sustained improvement in metabolic parameters, addressing the duration challenge by establishing a continuous therapeutic presence rather than intermittent effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions effectively decrease liver fat percentage, liver fibrosis score, NAFLD activity score, and metabolic disorder parameters by 10% or more, and enhance beneficial parameters like HDL cholesterol by 10% or more, providing therapeutic benefits for conditions like NAFLD, NASH, liver fibrosis, obesity, and heart diseases.
Implementation Method 1
the oligonucleotide comprises a small interfering RNA (siRNA) comprising a sense strand and an antisense strand
Implementation Method 2
the oligonucleotide comprises a modified internucleoside linkage... the oligonucleotide comprises a modified nucleoside
Data Source
AI summary
Disclosed herein are MS4A4E inhibitors such as oligonucleotides that target MS4A4E. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with MS4A4E mutations that include providing an MS4A4E inhibitor to a subject.